GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 … Continue reading GW Pharma Pre-Announces Q4 Revenue of $148 Million Ahead of Expectations